OBSN N Stock Overview
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ObsEva SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF1.60 |
| 52 Week High | CHF9.65 |
| 52 Week Low | CHF1.55 |
| Beta | 0.90 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -97.33% |
| 5 Year Change | -99.47% |
| Change since IPO | -99.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| OBSN N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how OBSN N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how OBSN N performed against the MX Market.
Price Volatility
| OBSN N volatility | |
|---|---|
| OBSN N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: OBSN N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OBSN N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 15 | Fabien de Ladonchamps | www.obseva.com |
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA Fundamentals Summary
| OBSN N fundamental statistics | |
|---|---|
| Market cap | Mex$123.16m |
| Earnings (TTM) | -Mex$500.12m |
| Revenue (TTM) | Mex$328.69m |
0.4x
P/S Ratio-0.2x
P/E RatioIs OBSN N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBSN N income statement (TTM) | |
|---|---|
| Revenue | US$19.64m |
| Cost of Revenue | US$10.71m |
| Gross Profit | US$8.93m |
| Other Expenses | US$38.81m |
| Earnings | -US$29.88m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 14, 2023
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 45.46% |
| Net Profit Margin | -152.16% |
| Debt/Equity Ratio | 32.9% |
How did OBSN N perform over the long term?
See historical performance and comparison